WASHINGTON — The U.S. Defense Department is getting set to push for a new vaccine against “Q-fever” bacteria, an agent with a reputation as a potential terrorism tool acquired in part through its history as a government-made biological weapon.
The Pentagon’s Defense Threat Reduction Agency is planning an online forum on Dec. 5 to facilitate conversation with potential developers of a vaccine against Q fever, which is also known by the bacteria’s formal designation, Coxiella burnetii.
The United States investigated the agent’s warfare potential and the Soviet Union fully weaponized it decades ago, long before both countries formally denounced biological arms in the 1970s. The disease also occurs in nature and has affected hundreds of U.S. troops deployed overseas.
It can produce fever, pneumonia, and numerous other symptoms associated with a variety of pathogens.
Certain antibiotics are considered effective against the bacteria, but no vaccine is presently sold in the United States, according to the Federation of American Scientists. An existing vaccination available abroad reportedly can cause side effects such as abscesses and swollen joints.
The United States “should definitely have a Q fever vaccine,” Amesh Adalja, a senior associate with the Center for Health Security at the University of Pittsburgh Medical Center, said in a phone interview. “This is still a disease that has some public health burden, in addition to its potential use as a bioweapon.”
The U.S.-led occupation of Iraq led to roughly 200 “acute” Q-fever cases among U.S. soldiers, the Centers for Disease Control and Prevention reported earlier this year.
Those infections appeared to result from unintentional exposure to animal carriers or bacteria swept up by helicopter rotors. Such naturally occurring cases rarely cause death, but Adalja suggested the agent could prove more dangerous if incorporated in a weapon.
Q-Fever bacteria infected but reportedly did not kill any conscientious war objectors deliberately exposed to the agent during U.S. Army experiments in the 1950s.
The United States has been eyeing a new Q-fever vaccine for several years. However, the agent’s status as a potential bioterrorism tool is fairly new, relative to how long it has been an established biological weapon. CDC officials only began tracking Q-fever infections in 1999, as the Clinton administration was increasing the nation’s focus on biological terrorism as a national-security threat.
A CDC list of potential bioterrorism agents and diseases, which includes Q fever, “is derived almost solely from the U.S. and Soviet bioweapons programs,” Adalja said. He suggested that the U.S. government is “substantially” more likely to fund development of vaccines and treatments for such agents than for pathogens never involved in government biological-weapons programs.
Agents more than dangerous than Q-fever may have emerged since the Cold-War height of the U.S. and Soviet biological-weapons programs, but the established track record of historical biological arms could make them particularly attractive to would-be bioterrorists, Adalja said.
This article was published in Global Security Newswire, which is produced independently by National Journal Group under contract with the Nuclear Threat Initiative. NTI is a nonprofit, nonpartisan group working to reduce global threats from nuclear, biological, and chemical weapons.
What We're Following See More »
Foreign Policy takes a look at the future of mining the estimated "100,000 near-Earth objects—including asteroids and comets—in the neighborhood of our planet. Some of these NEOs, as they’re called, are small. Others are substantial and potentially packed full of water and various important minerals, such as nickel, cobalt, and iron. One day, advocates believe, those objects will be tapped by variations on the equipment used in the coal mines of Kentucky or in the diamond mines of Africa. And for immense gain: According to industry experts, the contents of a single asteroid could be worth trillions of dollars." But the technology to get us there is only the first step. Experts say "a multinational body might emerge" to manage rights to NEOs, as well as a body of law, including an international court.
Not to be outdone by Jeffrey Goldberg's recent piece in The Atlantic about President Obama's foreign policy, the New York Times Magazine checks in with a longread on the president's economic legacy. In it, Obama is cognizant that the economic reality--73 straight months of growth--isn't matched by public perceptions. Some of that, he says, is due to a constant drumbeat from the right that "that denies any progress." But he also accepts some blame himself. “I mean, the truth of the matter is that if we had been able to more effectively communicate all the steps we had taken to the swing voter,” he said, “then we might have maintained a majority in the House or the Senate.”
Ronald Reagan's children and political allies took to the media and Twitter this week to chide funnyman Will Ferrell for his plans to play a dementia-addled Reagan in his second term in a new comedy entitled Reagan. In an open letter, Reagan's daughter Patti Davis tells Ferrell, who's also a producer on the movie, “Perhaps for your comedy you would like to visit some dementia facilities. I have—I didn’t find anything comedic there, and my hope would be that if you’re a decent human being, you wouldn’t either.” Michael Reagan, the president's son, tweeted, "What an Outrag....Alzheimers is not joke...It kills..You should be ashamed all of you." And former Rep. Joe Walsh called it an example of "Hollywood taking a shot at conservatives again."
In a sign that she’s ready to put a longer-than-expected primary battle behind her, former Secretary of State Hillary Clinton (D) is no longer going on the air in upcoming primary states. “Team Clinton hasn’t spent a single cent in … California, Indiana, Kentucky, Oregon and West Virginia, while” Sen. Bernie Sanders’ (I-VT) “campaign has spent a little more than $1 million in those same states.” Meanwhile, Sen. Jeff Merkley (D-OR), Sanders’ "lone backer in the Senate, said the candidate should end his presidential campaign if he’s losing to Hillary Clinton after the primary season concludes in June, breaking sharply with the candidate who is vowing to take his insurgent bid to the party convention in Philadelphia.”
The team behind the bestselling "Clinton Cash"—author Peter Schweizer and Breitbart's Stephen Bannon—is turning the book into a movie that will have its U.S. premiere just before the Democratic National Convention this summer. The film will get its global debut "next month in Cannes, France, during the Cannes Film Festival. (The movie is not a part of the festival, but will be shown at a screening arranged for distributors)." Bloomberg has a trailer up, pointing out that it's "less Ken Burns than Jerry Bruckheimer, featuring blood-drenched money, radical madrassas, and ominous footage of the Clintons."